Clinical Trial Update: The BEACON Study (Breast Cancer Outcomes With NKTR-102) [Phase 3]

View source ↗

Summary

Phase 3 BEACON study completed for NKTR-102 in locally recurrent and metastatic breast cancer; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• NKTR-102

Snippet

Sponsor: Nektar Therapeutics | Conditions: Locally Recurrent Breast Cancer, Metastatic Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-06-01